Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
Australia
Concord Hospital, Concord Peter MacCallum Cancer Centre, Melbourne Sir Charles Gairdner Hospital, Nedlands France
Institut Paoli-Calmettes, Marseille Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg